Skip to main content

Cellular therapy of corneal epithelial defect by adipose mesenchymal stem cell-derived epithelial progenitors



Persistent epithelial defects (PED), associated with limbal stem cell deficiency (LSCD), require ocular surface reconstruction with a stable corneal epithelium (CE). This study investigated CE reformation using human adipose mesenchymal stem cells (ADSC), which derived epithelial progenitors via mesenchymal-epithelial transition (MET).


STEMPRO human ADSC were cultured with specific inhibitors antagonizing glycogen synthase kinase-3 and transforming growth factor-β signaling, followed by culture under a defined progenitor cell targeted-epithelial differentiation condition to generate epithelial-like cells (MET-Epi), which were characterized for cell viability, mesenchymal, and epithelial phenotypes using immunofluorescence and flow cytometry. Tissue-engineered (TE) MET-Epi cells on fibrin gel were transplanted to corneal surface of the rat LSCD model caused by alkali injury. Epithelial healing, corneal edema, and haze grading, CE formation were assessed by fluorescein staining, slit lamp bio-microscopy, anterior segment optical coherence tomography, and immunohistochemistry.


CD73high/CD90high/CD105high/CD166high/CD14negative/CD31negative human ADSC underwent MET, giving viable epithelial-like progenitors expressing δNp63, CDH1 (E-cadherin), epidermal growth factor receptor, integrin-β4, and cytokeratin (CK)-5, 9. Under defined epithelial differentiation culture, these progenitors generated MET-Epi cells expressing cell junction proteins ZO1 and occludin. When transplanted onto rat corneal surface with LSCD-induced PED, TE-MET-Epi achieved more efficient epithelial healing, suppressed corneal edema, and opacities, when compared to corneas without treatment or transplanted with TE-ADSC. CE markers (CK3, 12, and CDH1) were expressed on TE-MET-Epi-transplanted corneas but not in other control groups.


Human ADSC-derived epithelial-like cells, via MET, recovered the CE from PED associated with LSCD. ADSC can be a viable adult stem cell source for potential autologous epithelial cell-based therapy for corneal surface disorders.


The corneal epithelium (CE) is the outermost layer of the cornea. It is about 50 μm thick and consists of 5–7 layers of the stratified squamous non-keratinized epithelium [1]. The basal layer contains cuboidal cells adhered to an underlying basement membrane, the Bowman’s membrane. The CE is a self-renewing tissue, owing to the epithelial stem cells (limbal stem cells, LSC) present in the limbal basal epithelium at the corneal periphery [2, 3]. This unique population of epithelial progenitors constantly provides new cells for normal epithelial turnover and wound healing. The transparent CE maintains corneal clarity and protects the eye against infection and damage while allowing nutrient transfer and gaseous exchange from tear fluid. A breach of CE integrity, due to mechanical trauma (like foreign body intrusion, contact lens overuse, and chemical burns); infection, neurotrophic keratopathy, dry eye, systemic and genetic disorders (e.g., thyroid eye diseases, Sjogren’s syndrome, aniridia-related keratopathy caused by Pax6 mutations, and ectodermal dysplasia caused by P63 mutations), and limbal stem cell deficiency (LSCD); causes persistent epithelial defects (PED), which result in corneal scarring, ulceration, neovascularization, conjunctivalization and, ultimately, corneal opacification, and visual loss [4].

The management of severe CE defects is challenging. When medical treatments fail and the defects or ulcer persist (for more than 3 weeks), conventional surgical treatments become indicated [5]. In severe cases, the disorders could have destroyed LSC population and compromised its regenerative capacity, resulting in LSCD. In bilateral total LSCD, there are no autologous cell sources to reconstruct the damaged ocular surface. Corneal grafting in these conditions is frequently indicated and demands a replacement of healthy corneolimbal epithelium, with stem cell population (keratolimbal grafting) from donor corneas [6]. Though it has shown significance in improving the visual acuity in patients with bilateral LSCD, allograft rejection remains the most common cause of long-term epithelial failure. Patients usually require a prolonged course of systemic immunosuppression, which could cause adverse effects, including hyperglycemia, elevated creatinine, and hypertension, as well as elevated intraocular pressure and cataract [7, 8]. Adult tissue-specific MSC (mesenchymal stem cells) have been introduced as an accessible and non-immunogenic stem cell source, with potential therapeutic value in CE regeneration and treatment of PED for corneal surface disorders [9, 10]. These multipotent cells have the capacity to differentiate towards adipocyte, chondrocyte, and osteoblasts [11, 12]. Human adipose-derived MSC (ADSC) incubated in culture media conditioned with human CE cells attained polygonal morphology and upregulated transforming growth factor-β (TGFβ) receptor (CD105) and cytokeratin (CK)-12 (CE marker) [13]. Rabbit bone marrow MSC co-cultured with LSC displayed CK3 expression [14]. Although there have been promising results of significant CE regeneration, healing of PED and vision recovery in animal models, and clinical trial, it remains uncertain whether MSC can transdifferentiate into CE cells [15, 16]. Other actions include the secretion of trophic factors and cytokines to stimulate the surviving resident cells to proliferate and to exert anti-inflammatory and immunomodulatory effects on the injured corneal tissue [17, 18]. Our group has reported the mesenchymal-epithelial transition (MET) of human ADSC into epithelial lineage via antagonizing GSK3 (glycogen synthase kinase 3) and TGFβ signaling [19]. It generated epithelial-like progenitors expressing E-cadherin (CDH1), cytokeratins, epithelial proliferation markers (δNp63 and proliferating cell nuclear antigen) with concomitant suppression of N-cadherin (CDH2), indicating MET progression.

In this study, we examined the therapeutic potential of these ADSC-derived epithelial progenitors on CE reconstruction in a rat alkali-burn induced total LSCD model. Cells grown on thin fibrin gel and differentiated to form tissue-engineered (TE) epithelial construct were transplanted to an injured corneal surface. The effect on corneal epithelial healing, opacity, and edema, as well as CE marker expression, was examined and compared to injured control without treatment or transplanted with ADSC on fibrin gel.


Human primary ADSC culture and characterization

Human ADSC (n = 3) from StemPro Human Adipose-Derived Stem Cell Kit (ThermoFisher, Waltham, MA, USA) were cultured at 104 cells/cm2 in MesenPRO RS™ medium (ThermoFisher) with 2% serum (provided in MesenPRO kit). Cells were subpassaged using TryPLE-Express (ThermoFisher). The multilineage differentiation potential was assessed by induced differentiation to adipocytes using StemPro Adipogenesis kit (ThermoFisher) to chondrocytes using the StemPro Chondrogenesis kit (ThermoFisher). The cells were stained with Oil Red O (Sigma-Aldrich, St. Louis, MI, USA) for adipocytes, toluidine blue (Sigma-Aldrich) for chondrocytes, and alizarin red S (Sigma-Aldrich) for osteocytes [19].

Mesenchymal-epithelial transition

Human ADSC at passage 2 were induced to undergo a mesenchymal-epithelial transition (MET) as previously reported [19] with modifications. A schematic diagram is depicted in Fig. 1. In brief, ADSC were placed in MET induction medium (M1) (Table 1) for 5 days. The culture was then changed to M2 medium with reduced VPA M and CHIR99021 concentration while other components were unchanged (Table 1). After M2 culture for 7 days, the cells were placed in M2/CNT-50 medium (CELLnTEC, Bern, Switzerland) (1:1 v/v) for 3 days, followed by CNT-50 for 10 days. Fresh medium was replenished every 3 days.

Fig. 1

A schematic diagram showing the small molecule-induced conversion of human ADSC to epithelial-like progenitors via mesenchymal-epithelial transition (MET) and further differentiation to generate epithelial cells (MET-Epi). The cell sheet was tissue-engineered on fibrin gel to prepare construct for transplantation

Table 1 Media formulation

Tissue-engineered cells on fibrin gel construct

Plasminogen-free fibrinogen powder (Baxter, Singapore) was reconstituted in saline at a concentration of 5.3 mg/ml. Thrombin powder (Baxter) was dissolved in 0.9 mM calcium chloride at a concentration of 4 IU/ml. Fibrin gel (300 μl volume) was prepared by mixing fibrinogen with thrombin at 0.024 IU/ml and casted on culture insert at 37 °C for an hour for polymerization. Prior to cell seeding, the fibrin gel was rinsed with CNT-50 thrice to remove any unpolymerized molecules. ADSC-derived MET cells were seeded on fibrin gel surface at 5 × 104 cells/cm2 in CNT50 medium (Fig. 1). Upon confluence, the cell/fibrin gel construct was airlifted by lowering the level of culture medium (CNT50 added with 0.5 IU/ml aprotinin) to submerge at the base of the culture insert. The construct was kept moist with sterile saline. After 7 days of stratification to cell multilayering, the construct was collected for transplantation. In parallel, human ADSC (without MET) were cultured on fibrin gel and underwent airlifting to provide a control construct for animal experiment. For human cell tracking, the epithelial construct was incubated with Molday ION Evergreen™ reagent (1:200 dilution; BioPAL, Worcester, MA, USA) for 48 h before surgery.

Flow cytometry

Cell suspension after TryPLE digestion from culture was fixed with neutral-buffered 2% paraformaldehyde and blocked with 2% bovine serum albumin (BSA) and 2% normal goat serum (NGS, Sigma-Aldrich). The samples were incubated with antibodies against cell surface epitopes (CD14, 31, 73, 90, 105, 166, EGFR, ITGB4, OCLN and ZO1 (Additional file 1: Table S1), followed by AlexFluor488-conjugated IgG (Invitrogen). For the detection of intracellular epitopes (CDH1 and CDH2) (Additional file 1: Table S1), the cell samples were permeabilized with 1% Triton X-100 before blocking and antibody incubation. The staining signal was analyzed by FACSVerse System (BD Biosciences) with a minimum of 10,000 events in each experiment.


Cells grown on chamber slides (Lab-Tek II, Nunc) were fixed with neutral-buffered 2% paraformaldehyde, saponin-permeabilized, blocked with 2% BSA and NGS and incubated with antibodies (Additional file 1: Table S1) for 2 h at room temperature. After buffer washes, the samples were stained with AlexaFluor488 or 594-conjugated IgG antibody (Jackson ImmunoRes lab, West Grove, PA, USA), followed by mounting with Fluoroshield with DAPI (4′,6-diamidino-2-phenylindole; Santa Cruz Biotech., Santa Cruz, CA, USA) and viewed under fluorescence microscopy (Axioplan 2, Carl Zeiss, Oberkochen, Germany).

Cell viability

The cell culture was incubated with MTT (3–4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide, 0.5 mg/ml) for 4 h, followed by addition of dimethylsulfoxide (DMSO, Sigma-Aldrich) to a final concentration of 5% to dissolve the formazan crystals. After centrifugation at 350 g for 5 min, the supernatant was collected and the optical density was measured at 560 nm (excitation) with a reference filter of 620 nm using a microplate reader (INFINITE 200, Tecan, Mannedorf, Switzerland). The relative cell number was calculated as the ratio of the optical density of cells under M1 or M2 culture to that of cells in MesenPRO™ culture. Experiments were done in triplicate.

Rat LSCD model after alkali injury

Sprague-Dawley rats (4–8 weeks old, n = 24) were treated according to the regulation of the ARVO statement for the Use of Animals in Ophthalmic and Vision Research. The experimental protocol was approved by The Institutional Animal Care and Use Committee of SingHealth, Singapore (2012/SHS/768). Rats were anesthetized by intraperitoneal xylazine (5 mg/kg; Troy Laboratories, Glendenning, NSW, Australia) and ketamine hydrochloride (50 mg/kg; Parnell Laboratories, Alexandria, NSW, Australia). The eyes were rinsed with normal saline and anesthetized with topical lidocaine hydrochloride (1%; Pfizer Laboratories, NY, USA). Alkali injury was performed on the right eyes, after sterilization with povidone-iodine (Prodine, ICM Pharma, Singapore). A circular filter paper (4 mm inner diameter and 6 mm diameter) soaked in 0.5 N sodium hydroxide solution was placed on the corneal surface for 30 s, which was then washed with normal saline for 1 min with a minimum of 10 ml normal saline. CE was completely removed by gentle scraping with a #64 surgical blade. A 360° limbal peritomy was conducted to create total LSCD. After rinsing with normal saline, the corneal surface was ready for transplantation.

Transplantation of TE cell/fibrin gel constructs

The rats were randomly placed in four groups for transplantation. Group 1: TE-MET-Epi/fibrin gel construct; group 2: TE-ADSC/fibrin gel construct; group 3: fibrin gel only, and group 4: untreated injured control. Immediately after alkali injury and peritomy, the cornea surface was extensively rinsed normal saline. The constructs were trimmed to the appropriate size covering the corneal surface and placed with fibrin gel in contact with the stromal bed. The implant was secured with 8 interrupted sutures using 10/0 nylon suture equably on the conjunctiva. Eyelids were closed with 2 temporary tarsorrhaphy sutures using 6/0 silk, which were removed after 7 days. All operated eyes received topical tobramycin (1%, Alcon, Geneve, Switzerland) and dexamethasone phosphate (0.1%, Alcon), 4 times daily. Rats were sacrificed after 4 weeks by overdosed pentobarbital (85 mg/kg; Jurox, Rutherford, NSW, Australia) intraperitoneally and corneas were harvested for immunohistochemistry.

Ophthalmic examination and measurements

All corneal imaging and measurements were conducted 3 days prior to injury (pre-operative) and weekly post-transplantation for a total of 4 weeks. Slit-lamp micrographs were taken using a Zoom Slit Lamp NS-2D (Righton, Tokyo, Japan). Two independent observers (FB, GY) graded the corneal clarity and haze formation from 0 to 4 under slit-lamp examination [20]. Grade 0 corresponded to a totally clear cornea; grade 1 to minimal haze under direct and diffuse illumination; grade 2 to mild haze easily visible under direct focal slit illumination; grade 3 to moderate haze/opacities that partially obscured the iris details; and grade 4 to severe dense opacities that obscured completely the details of the anterior segment. Corneal epithelial wound closure was assessed by staining with 1% Minims fluorescein sodium solution (Bausch & Lomb, Rochester, NY, USA) for 5 s, followed by sterile saline rinsing, and visualized by digital camera photography in cobalt blue light with ultraviolet light filters [21]. The wound area (with fluorescein label) was determined by a color threshold technique of ImageJ (Fiji) software and expressed as a percentage of total corneal area. Corneal cross-section visualization and measurement of central corneal thickness (CCT) were done using anterior segment optical coherence tomography (AS-OCT, RT-Optovue™, Carl Zeiss Meditec, Dublin, CA, USA). CCT was calculated as the mean of 3 measurements taken at the corneal midpoint and at 0.3 mm on either side [22].

Rat cornea processing for histochemistry and immunofluorescence

Excised corneas were fixed in neutral-buffered 4% paraformaldehyde for 2 h and cut into equal halves. One part was embedded in Optimum Cutting Temperature (OCT) cryo-compound (Leica Microsystems, Nussloch, Germany) and cryosections (6 μm thick) were obtained for immunofluorescence using antibodies against CDH1, CDH2, CK3, and CK12 (Additional file 1: Table S1). The other corneal half was fixed in 10% formalin (Sigma) for overnight, buffer washed, dehydrated, and processed for paraffin embedding. Sections (5 μm thick) were dewaxed, hydrated, stained with hematoxylin and eosin reagents, and viewed under light microscopy (Axioplan 2).

Statistical analyses

All data were expressed as mean ± SD. Results from in vivo experiments were analyzed with Prism 6.0 software (GraphPad, San Diego, CA, USA). A comparison of fold changes of marker expression between cell types was assessed by the Mann-Whitney U test. Statistical differences for corneal wound areas were determined by ANOVA. P < 0.05 was considered statistically significant.


Human ADSC characterization

Primary human ADSC were propagated in MesenPRO™ medium to passage 2. Flow cytometric analysis showed high expression rate of standard MSC markers, which were CD73 at 99.5 ± 0.3%, CD90 at 92.2 ± 12.4%, CD105 at 99.4 ± 0.5%, and CD166 at 99.5 ± 0.4%. The expression rate of monocyte-related CD14 was < 4% and hematopoietic-related CD31 was 0.8% (Additional file 1: Figure S1). Multipotency was demonstrated by defined differentiation protocols for adipogenesis, chondrogenesis, and osteogenesis. The treated cells under respective conditions were stained positive to Oil Red O for adipocytes, toluidine blue for chondrocytes, and Alizarin Red S for osteocytes (Additional file 1: Figure S2).

Mesenchymal-epithelial transition of human ADSC to express epithelial phenotype

CD73high/CD90high/CD105high/CD166high/CD14negative/CD31negative ADSC were treated with small molecules inhibiting GSK3 and TGFβ signaling together with atRA, as previously reported [19] with minor modifications (Fig. 1). After M1 culture for 5 days, the cells were placed in a revised step with a 7-day culture in M2 medium, which had similar formulation as M1, except the reduced concentration of VPA at 50 μM and CHIR99021 at 300 nM. This adjustment substantially improved cell viability. Using MTT assay, the cell viability after M1 culture step was 73.6% and this was greatly improved when the cells were changed to M2 condition (99.3% viability) (Fig. 2a). Phase-contrast micrographs showed that M2 cultured cells had similar morphology as M1 cultured cells. Both cultures were densely packed and cells were polygonal in shape (Fig. 2b). In contrast, ADSC under MesenPRO™ culture were slender and bipolar in shape with the presence of intercellular space. Under immunofluorescence, M2 cultured MET progenitors expressed CDH1 (E-cadherin, a MET hallmark marker) at both cytoplasmic and cell surface location and δNp63 (a cell proliferation marker of epithelial progenitors) was predominantly nuclear (Fig. 3a). By flow cytometry, there was a general induction of epithelial-related genes after M2 culture (Fig. 3b). CK5 expression was detected in 74% MET progenitors compared to 10% in untreated ADSC. Likewise, CK19 expression was found in 26.5% MET progenitors and only in 1.8% ADSC. Epidermal growth factor receptor (EGFR) was detected in 4.5% MET progenitors but in 0.1% ADSC and integrin-β4 (ITGB4) was expressed in 4% MET progenitors but undetected in ADSC. These results demonstrated that small molecule treatment under M1 and M2 cultures on ADSC generated epithelial-like progenitors through MET.

Fig. 2

Small molecule treatment of human ADSC to MET-Epi cells. a Cell viability measured by MTT assay showed M2 medium caused negligible toxicity, when compared to M1 medium. b Phase-contrast micrographs of (i) human ADSC propagated in MesenPRO™ medium, (ii) MET cells after M1 culture for 5 days, (iii) MET cells after M2 culture for 7 days, and (iv) MET-Epi cells after CNT50 culture for 7 days. Scale bars 50 μm

Fig. 3

Characterization of MET progenitors. a Immunofluorescence showing an induction of nuclear dNp63 and CDH1 (located in the cytoplasm and cell surface) in MET progenitors. Phalloidin was expressed in both human ADSC and MET progenitors. b Flow cytometry analysis demonstrating the elevated number of MET progenitors expressing CK5, CK19, EGFR, and ITGB4. Scale bars 10 μm

Differentiation of MET epithelial progenitors

The culture of MET progenitors in CNT50 medium gradually induced more epithelial marker expression. Flow cytometric analysis revealed that 97.2 ± 4.8% cells expressed OCLN and 83.3 ± 4.2% cells expressed ZO1 (Fig. 4a). This was also illustrated by immunofluorescence that both OCLN and ZO1 were expressed on the cell surface (Fig. 4b). These cells were termed as MET-Epi cells. In return, the mesenchymal marker, CDH2 (N-cadherin) was downregulated in MET-Epi cells, when compared to ADSC.

Fig. 4

MET-derived epithelial (MET-Epi) cell characterization. a Flow cytometry showed an increased number of MET-Epi cells expressing OCLN and ZO1 after CNT50 culture. b Immunofluorescence showing the downregulated CDH2 (NCAD) and upregulated OCLN and ZO1 on the cell surface in MET-Epi cells, compared to ADSC. Scale bar 20 μm

Transplantation of tissue-engineered MET-Epi cells on fibrin gel to alkali injured rat corneal surface

Recovery of corneal clarity

In the first week post-transplantation, the corneas had considerable haze, which was cleared after 4 weeks (Fig. 5a). The corneas were stable and had minimal neovascularization. Corneal haze grading showed that the corneas at the first-week post-transplantation had a haze score of 3 ± 0.96 (Fig. 5d). This was substantially reduced to score level 1 after 4 weeks (P < 0.01, n = 6; Mann-Whitney U test). In contrast, injured corneas without grafting remained opaque and extensively vascularized. The mean haze scores were above 3 throughout different weeks of examination. Injured rat corneas receiving fibrin gel only and TE-ADSC remained hazy and the scores were greater than 2 up to 4 weeks post-surgery.

Fig. 5

Mouse corneal changes after transplantation of tissue-engineered cell/fibrin gel construct to alkali-injured corneal surface. a. Slit-lamp biomicroscopy showing recovery of the clear cornea at week 1 and 4 post-transplantation of TE-MET-Epi constructs. In contrast, alkali-injured corneas were completely opaque and vascularized. b Fluorescein staining pictures showing re-epithelialization of corneal surface after TE-MET-Epi transplantation, whereas injured corneas developed epithelial defect and vascularization. c Anterior segment OCT showing the corneal thickness after TE-MET-Epi transplantation was similar as the normal cornea and injured corneas remained thicker. d Haze grading. e Percentage changes of the epithelial defect. f Central corneal thickness changes

Improved corneal epithelial healing

Sodium fluorescein stains for corneal stroma but not the intact corneal epithelium, and this demarcates the area with the epithelial loss [23]. When compared to injured corneas without treatment, all groups transplanted with fibrin gel with or without TE cell sheet showed reduced fluorescein intensity, indicating the healing of epithelial defect (Fig. 5b). At 4th week post-surgery, there was 16 ± 5.6% corneal surface with epithelial defects in an untreated injured group whereas < 2% was detected in groups with transplantation (P < 0.05) (Fig. 5e). Among different grafts, TE-MET-Epi group showed the fastest epithelial healing. At week 2 post-transplantation, the epithelial defect was 3.2 ± 2.5% for TE-MET-Epi group, whereas TE-ADSC group had 11.8 ± 10.1% and the group with fibrin gel only had 11.8 ± 5.6%. These groups showed similar defect percentages in the third and fourth week (all were < 2%).

Restoration of corneal thickness

The cross-section image of corneas under AS-OCT showed that corneal edema occurred in all groups in the first-week post-surgery (Fig. 5c). The mean CCT was increased by 142% in TE-MET-Epi group, 83% in TE-ADSC group, 114% for fibrin gel only and 178% in the untreated injured group (Fig. 5f). The CCT of TE-MET-Epi group gradually decreased to the pre-injury level at the fourth-week post-surgery (P < 0.05, compared to untreated injured control). In contrast, corneas receiving TE-ADSC or fibrin gel only had slightly thicker corneas (an increase of 67% for TE-ADSC and 65% for fibrin gel only). The untreated injured corneas remained much thicker (an increase of 269%).

Reconstruction of corneal epithelium

Histology showed that corneas grafted with TE-MET-Epi for 4 weeks exhibited intact multilayered epithelia, similar to the normal corneas (Fig. 6a). The reconstructed epithelia appeared regular and smooth with 3–5 cell layers in the central region. The detection of Molday-ION Evergreen signals in transplanted rat corneas showed the presence of human MET-Epi cells predominantly in the basal epithelial layers (Fig. 6b). This was validated by a similar expression of human-specific nuclear antigen (HuNu) (Fig. 6b). The keratocytes in the anterior corneal stroma were regularly aligned among the stromal lamellae with minimal detection of immune and inflammatory cells (Fig. 6a). By immunofluorescence, various corneal epithelial markers (CK3, 12, and CDH1) were positively detected, while the expression of CDH2 (mesenchymal marker) was negligible (Fig. 6c). In contrast, rat corneas of TE-ADSC group displayed a thinner cell layer with an irregular thickness (Fig. 6a). There was no expression of CK3, 12, and CDH1, whereas CDH2 was mildly detected (Fig. 6c). In untreated injured corneas, the epithelia were thicker and irregular (Fig. 6a). Polymorphonuclear cells (suggesting lymphocytes) were observed in the basal epithelial and anterior stroma.

Fig. 6

Corneal tissue changes after transplantation of tissue-engineered cell/fibrin gel constructs to the alkali-injured corneal surface. a. Representative H&E images of corneas. b Homing of Molday-ION Evergreen™ labeled human MET-Epi cells in the cornea (predominantly in basal layers) at week 4 post-transplantation. Similar result was revealed by human-specific HuNu staining (arrows). c Immunofluorescence of corneal epithelial marker expression at 4 weeks post-transplantation. CK3, CK12, and CDH1 (E-cadherin) were upregulated in reconstructed epithelial layers after TE-MET-Epi transplantation, but not in TE-ADSC transplanted group. In contrast, CDH2 (N-cadherin) was suppressed in TE-MET-Epi transplanted corneas. Scale bars: 0.1 mm


In this study, we demonstrated that ADSC could be a viable cell source to generate tissue-engineered (TE) epithelium on bioscaffold for treating persistent epithelial defects (PED) on the corneal surface. The epithelial-like progenitors derived from human ADSC via induced mesenchymal-epithelial transition (MET) were able to differentiate into epithelial cells, which developed into the multilayered epithelium, when cultured on fibrin gel support. The transplantation of this TE-MET-Epi to the corneal surface of a rat total LSCD model, achieved an efficient epithelial healing and suppressed corneal edema and opacities, when compared to injured corneas without treatment or transplanted with TE-ADSC constructs.

The clinical management of bilateral total LSCD is very challenging. Patients often present with PED and corneal instability, e.g., large ulcers that are prone to infection, and have a high risk of corneal melting and perforation [24,25,26]. Other aggravating conditions, such as lacrimal dysfunction, conjunctivalization, neovascularization, and keratinization, are also common and associated with a higher risk of graft failure in the event of keratoplasty [27]. The criteria of clinical success are the resolution of PED, regression of conjunctivalization and vascularization, and re-establishment of a stable and transparent corneal epithelium (CE). Few treatment options have been shown to be relatively effective for total LSCD.

Allogeneic keratolimbal grafting is a reconstructive surgical procedure but is accompanied by a risk of rejection due to HLA incompatibility, hence it requires prolonged systemic immune suppression [28]. COMET (cultivated oral mucosal epithelium transplantation) using autologous epithelial cells of non-ocular origin is an option to overcome these drawbacks while re-establishing a stable and transparent epithelium [29,30,31,32]. However, the corneal surface stability declined gradually in the first 6 months and remained stable in only 50 to 60% of treated eyes thereafter. The failed cases had a recurrence of CE defects and ocular complications, such as corneal melting, perforation, and neovascularization [25, 33]. An alternative option is a Boston keratoprosthesis, however, it is an invasive procedure, which changes the eye anatomy and physiology drastically and irreversibly [34, 35]. Despite the improvements in visual function, there are frequent risks of ocular complications, such as glaucoma development and progression of pre-existing glaucoma [36, 37]. Hence, vigorous peri-operative management and long-term follow-up are required. Alternative procedures that provide satisfactory visual rehabilitation with less complications and long-term corneal stability are needed.

Renewal cell sources of embryonic stem (ES) cells and induced pluripotent stem cells (iPSC) have been explored for stem cell-based therapy in wounded corneas [38]. Several reports have illustrated the differentiation potency of these pluripotent cells to CE-like cells via ex vivo induction with cytokines and growth factors, as well as extracellular support [39,40,41,42]. Nonetheless, the critical issues concerning the risk of tumorigenesis, high procedure cost, and the reproducibility and homogeneity of epithelial differentiation remain to be tackled before any consideration for clinical use [43, 44]. Other studies using hair follicle stem cells, dental pulp stem cells, and umbilical cord stem cells are still in the experimental stage and further investigation is required to refine and improve the differentiation efficiency towards CE lineage [45,46,47].

MSC represent a non-immunogenic source of multipotent stem cells that are available in adult tissues. Several preclinical and clinical studies have reported their potential therapeutic values in healing and regenerating CE, improving corneal transparency and vision [48,49,50]. Human ADSC were well-tolerated on rabbit corneas, and they reduced corneal inflammation, neovascularization, and opacity in a rabbit LSCD model [51]. Moreover, epithelial-like cells transdifferentiated from rabbit ADSC using limbal condition media culture regenerated clear and smooth corneas with epithelial-specific CK3/12 expression in rabbit corneas having LSCD [52]. In a clinical trial of 28 LSCD patients receiving allogeneic bone marrow MSC and allogeneic cultivated limbal epithelium, respectively, MSC transplantation was safe and improved the CE phenotype in 71% cases, which was comparable to cultivated limbal epithelium (CE reformation in 67% cases), at 12 months post-surgery ( number, NCT01562002) [16]. These results favor the application of MSC in healing the diseased CE due to LSCD.

The underlying effects of MSC on the damaged ocular surface can involve multiple mechanisms [9]. Whether MSC can transdifferentiate into CE cells is still uncertain. On the other hand, the capacity of MSC in secreting trophic and growth factors, small RNAs via extracellular vesicles or exosomes, could exert anti-inflammatory and immunomodulatory effects and to stimulate resident viable cells to survive and proliferate, hence reducing tissue injury [10, 17]. In addition, the secretome of ADSC can suppress epithelial-mesenchymal transition (EMT) of diseased CE, in attenuating fibrosis and restoring the corneal transparency [53].

Our work specifically focused on MSC transdifferentiation into CE cells. Previously, we reported an ex vivo culture of human ADSC with a combination of small molecules antagonizing GSK3 and TGFβ signaling to generate epithelial-like progenitors with substantially upregulated CDH1 (E-cadherin) and downregulated mesenchymal gene CDH2 (N-cadherin) expression [19], which is the hallmark of MET [54]. In the present study, these MET progenitors were proliferative to generate cells expressing δNp63 (an epithelial proliferation marker), CDH1, CK5 and 19, epidermal growth factor receptor (EGFR), and integrin-β4 (ITGB4), indicating a commitment to epithelial lineage. When cultured under a defined progenitor cell-targeted (PCT)-epithelial differentiation condition, these MET progenitors formed intact epithelium with densely populated cobblestone-like cells expressing cell junction proteins, ZO1, and occludin. Hence, human ADSC, via an intermediate MET progenitor stage, were able to proliferate and differentiate into cells expressing epithelial-associated phenotype and further generate confluent epithelia.

To prepare for translational use on the corneal surface, these MET progenitors were able to adhere and proliferate on a cross-linked fibrin gel, which acts as a biological substrate to support cell expansion and differentiation [55]. To maintain the intact epithelium on fibrin gel, we added a protease inhibitor aprotinin to prevent gel degradation during culture [56]. This fabrication of tissue-engineered (TE) epithelium from MET progenitors created a transportable, pliable, and stable construct (TE-MET-Epi) ready for transplantation. There was competing interest in this invention.

Using a rat alkali-induced total LSCD model, the transplantation of TE-MET-Epi was shown to restore CE and stabilize the ocular surface. Up to 4 weeks post-surgery, human MET-Epi cells prelabeled with Molday-ION Evergreen™ were detected and predominantly homed to the basal epithelial layers, indicating the role in maintaining the multilayered corneal epithelium. This could associate with the faster epithelial healing and better resolution of corneal edema and haze in the TE-MET-Epi group than others with TE-ADSC, fibrin gel only, or untreated control. The central corneal thickness and haze score were close to the pre-operative values. On the treated corneas of TE-MET-Epi group, the cells colonizing on the corneal surface expressed CDH1 (ECAD) but not CDH2 (NCAD), which indicated the epithelial feature; and this was consistent to our previous results for MET progenitors [19]. The generated epithelia also expressed standard CE markers (CK3 and 12) that were undetectable for rat conjunctival cells. In contrast, rat corneas in TE-ADSC group expressed CDH2 but not CK3 and 12, indicating that they were unable to generate specific CE phenotype. For the alkali-injured cornea controls, the expression of CK4 and 19 illustrated the conjunctival epithelial cells, as a result of conjunctivalization, a consequence of conjunctival epithelial invasion after limbal destruction. In conclusion, the epithelial-like progenitors derived from ADSC, via MET, could differentiate into cells expressing CE markers and form an intact CE in restoring epithelial defects of LSCD.

In our model, the treatment outcome could be influenced by 1 week of tarsorrhaphy (eyelid closure); however, this was essential to prevent implant dislocation, as the rats might rub their eyes vigorously; and the same procedure was performed in all groups. The closed corneal surface reduced the exposure of MET-Epi cells to air-liquid interphase that could have hindered the epithelial cell polarization and differentiation [57]. Further evaluation using large animals may avoid the procedure of eyelid closure and the implant could be covered and protected by amniotic membrane [58]. In addition, ADSC are known to have the potential to augment angiogenesis [59], which functionally recovers ischemia-induced injuries [60]. However, this effect seemed to be diminished in MET-Epi cells derived from ADSC, and the transplanted corneas had reduced corneal neovascularization. Our further work will investigate the effect of MET on the expression of paracrine factors from ADSC on pro-angiogenesis (e.g., vascular endothelial growth factor-A, platelet-derived growth factor BB, basic fibroblast growth factor) and anti-angiogenesis (e.g., thrombospondin-1), and how these changes influence the corneal epithelial regeneration and stability. For potential clinical application, the TE epithelia from ADSC-derived MET cells can be fabricated in an autologous and xenofree fashion. Bioengineered recombinant human fibrin is safe without the risk of blood-borne pathogen transmission, has equivalent or better tensile strength than plasma-derived fibrin, and can be amenable to large-scale production [61]. It has been shown to maintain MSC viability and growth behavior, and cell delivery to the target site [62]. Our study showed that ADSC-derived epithelial cells on fibrin gel construct were able to recover the defective corneal surface. Further studies will involve the long-term and quantitative assessment of CE recovery and stability as well as corneal haze reduction.


In this study, we demonstrated that human ADSC-derived MET progenitors generated TE-MET-Epi constructs, which significantly improved the CE recovery with efficient re-epithelialization and a more stable corneal surface, compared to other treatment arms, in a rat alkali-induced LSCD model. These results add to the field of stem cell therapy for corneal surface disorders by confirming the safety, non-immunogenicity, and potential clinical advantages using this mode of stem cell-based treatment for corneal epithelial disorders associated with bilateral LSCD.

Availability of data and materials

All data are included in the text and supplementary information.



Adipose mesenchymal stem cells


Anterior segment optical coherence tomography


Bovine serum albumin


Central corneal thickness


Corneal epithelium




Epidermal growth factor receptor


Epithelial-mesenchymal transition


Glycogen synthase kinase 3


Integrin β4


Limbal stem cell deficiency


Mesenchymal-epithelial transition


Normal goat serum


Mesenchymal stem cells


Persistent epithelial defect




Transforming growth factor β


  1. 1.

    Sridhar MS. Anatomy of cornea and ocular surface. Indian J Ophthalmol. 2018;66:190–4.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Kruse FE. Stem cells and corneal epithelial regeneration. Eye. 1994;8(Pt 2):170–83.

    PubMed  Article  Google Scholar 

  3. 3.

    Dua HS, Shanmuganathan VA, Powell-Richards AO, Tighe PJ, Joseph A. Limbal epithelial crypts: a novel anatomical structure and a putative limbal stem cell niche. Br J Ophthalmol. 2005;89:529–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Dua HS, Saini JS, Azuara-Blanco A, Gupta P. Limbal stem cell deficiency: concept, aetiology, clinical presentation, diagnosis and management. Indian J Ophthalmol. 2000;48:83–92.

    CAS  PubMed  Google Scholar 

  5. 5.

    McCulley JP, Horowitz B, Husseini ZM, Horowitz M. Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group. Trans Am Ophthalmol Soc. 1993;91:367–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Inatomi T, Nakamura T, Kojyo M, Koizumi N, Sotozono C, Kinoshita S. Ocular surface reconstruction with combination of cultivated autologous oral mucosal epithelial transplantation and penetrating keratoplasty. Am J Ophthalmol. 2006;142:757–64.

    PubMed  Article  Google Scholar 

  7. 7.

    Holland EJ, Mogilishetty G, Skeens HM, Hair DB, Neff KD, Biber JM, et al. Systemic immunosuppression in ocular surface stem cell transplantation: results of a 10-year experience. Cornea. 2012;31:655–61.

    PubMed  Article  Google Scholar 

  8. 8.

    Eslani M, Haq Z, Movahedan A, Moss A, Baradaran-Rafii A, Mogilishetty G, et al. Late acute rejection after allograft limbal stem cell transplantation: evidence for long-term donor survival. Cornea. 2017;36:26–31.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Mansoor H, Ong HS, Riau AK, Stanzel TP, Mehta JS, Yam GH. Current trends and future perspective of mesenchymal stem cells and exosomes in corneal diseases. Int J Mol Sci. 2019;20(12).

    PubMed Central  Article  PubMed  Google Scholar 

  10. 10.

    Nieto-Miguel T, Galindo S, Lopez-Paniagua M, Perez I, Herreras JM, Calonge M. Cell therapy using extraocular mesenchymal stem cells. In: Alió J, Alió del Barrio J, Arnalich-Montiel F, editors. Corneal Regeneration Essentials in Ophthalmology. Cham: Springer; 2019. p. 231–62.

    Google Scholar 

  11. 11.

    Rohban R, Pieber TR. Mesenchymal stem and progenitor cells in regeneration: tissue specificity and regenerative potential. Stem Cells Int. 2017;2017:5173732.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  12. 12.

    Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Trans Med. 2017;6:2173–85.

    Article  Google Scholar 

  13. 13.

    Nieto-Miguel T, Galindo S, Reinoso R, Corell A, Martino M, Perez-Simon JA, et al. In vitro simulation of corneal epithelium microenvironment induces a corneal epithelial-like cell phenotype from human adipose tissue mesenchymal stem cells. Curr Eye Res. 2013;38:933–44.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Gu S, Xing C, Han J, Tso MO, Hong J. Differentiation of rabbit bone marrow mesenchymal stem cells into corneal epithelial cells in vivo and ex vivo. Mol Vis. 2009;15:99–107.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Di G, Qi X, Zhao X, Zhang S, Danielson P, Zhou Q. Corneal epithelium-derived neurotrophic factors promote nerve regeneration. Invest Ophthalmol Vis Sci. 2017;58:4695–702.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Calonge M, Perez I, Galindo S, Nieto-Miguel T, Lopez-Paniagua M, Fernandez I, et al. A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency. Trans Res. 2019;206:18–40.

    Article  Google Scholar 

  17. 17.

    Samaeekia R, Rabiee B, Putra I, Shen X, Park YJ, Hematti P, et al. Effect of human corneal mesenchymal stromal cell-derived exosomes on corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2018;59:5194–200.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Fernandes-Cunha GM, Na KS, Putra I, Lee HJ, Hull S, Cheng YC, et al. Corneal wound healing effects of mesenchymal stem cell secretome delivered within a viscoelastic gel carrier. Stem Cells Trans Med. 2019;8:478–89.

    CAS  Article  Google Scholar 

  19. 19.

    Setiawan M, Tan XW, Goh TW, Yam GH, Mehta JS. Inhibiting glycogen synthase kinase-3 and transforming growth factor-beta signaling to promote epithelial transition of human adipose mesenchymal stem cells. Biochem Biophys Res Comm. 2017;490:1381–8.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Fantes FE, Hanna KD, Waring GO 3rd, Pouliquen Y, Thompson KP, Savoldelli M. Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys. Arch Ophthalmol. 1990;108:665–75.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  21. 21.

    Tong L, Png E, Aihua H, Yong SS, Yeo HL, Riau A, et al. Molecular mechanism of transglutaminase-2 in corneal epithelial migration and adhesion. Biochim Biophys Acta. 1833;2013:1304–15.

    Google Scholar 

  22. 22.

    Yam GH, Fuest M, Yusoff N, Goh TW, Bandeira F, Setiawan M, et al. Safety and feasibility of intrastromal injection of cultivated human corneal stromal keratocytes as cell-based therapy for corneal opacities. Invest Ophthalmol Vis Sci. 2018;59:3340–54.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Wilson G, Ren H, Laurent J. Corneal epithelial fluorescein staining. J Am Optom Assoc. 1995;66:435–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Sotozono C, Inagaki K, Fujita A, Koizumi N, Sano Y, Inatomi T, et al. Methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections in the cornea. Cornea. 2002;21:S94–101.

    PubMed  Article  Google Scholar 

  25. 25.

    Sotozono C, Inatomi T, Nakamura T, Koizumi N, Yokoi N, Ueta M, et al. Visual improvement after cultivated oral mucosal epithelial transplantation. Ophthalmology. 2013;120:193–200.

    PubMed  Article  Google Scholar 

  26. 26.

    Vazirani J, Nair D, Shanbhag S, Wurity S, Ranjan A, Sangwan V. Limbal stem cell deficiency - demography and underlying causes. Am J Ophthalmol. 2018;188:99–103.

    PubMed  Article  Google Scholar 

  27. 27.

    Shimazaki J, Shimmura S, Fujishima H, Tsubota K. Association of preoperative tear function with surgical outcome in severe Stevens-Johnson syndrome. Ophthalmology. 2000;107:1518–23.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Solomon A, Ellies P, Anderson DF, Touhami A, Grueterich M, Espana EM, et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology. 2002;109:1159–66.

    PubMed  Article  Google Scholar 

  29. 29.

    Nakamura T, Takeda K, Inatomi T, Sotozono C, Kinoshita S. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. Br J Ophthalmol. 2011;95:942–6.

    PubMed  Article  Google Scholar 

  30. 30.

    Satake Y, Higa K, Tsubota K, Shimazaki J. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. Ophthalmology. 2011;118:1524–30.

    PubMed  Article  Google Scholar 

  31. 31.

    Kolli S, Ahmad S, Mudhar HS, Meeny A, Lako M, Figueiredo FC. Successful application of ex vivo expanded human autologous oral mucosal epithelium for the treatment of total bilateral limbal stem cell deficiency. Stem Cells. 2014;32:2135–46.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Prabhasawat P, Ekpo P, Uiprasertkul M, Chotikavanich S, Tesavibul N, Pornpanich K, et al. Long-term result of autologous cultivated oral mucosal epithelial transplantation for severe ocular surface disease. Cell Tissue Banking. 2016;17:491–503.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Kanayama S, Nishida K, Yamato M, Hayashi R, Sugiyama H, Soma T, et al. Analysis of angiogenesis induced by cultured corneal and oral mucosal epithelial cell sheets in vitro. Exp Eye Res. 2007;85:772–81.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Avadhanam VS, Liu CS. A brief review of Boston type-1 and osteo-odonto keratoprostheses. Br J Ophthalmol. 2015;99:878–87.

    PubMed  Article  Google Scholar 

  35. 35.

    Salvador-Culla B, Kolovou PE. Keratoprosthesis: a review of recent advances in the field. J Funct Biomater. 2016;7(2).

    PubMed Central  Article  PubMed  Google Scholar 

  36. 36.

    Kamyar R, Weizer JS, de Paula FH, Stein JD, Moroi SE, John D, et al. Glaucoma associated with Boston type I keratoprosthesis. Cornea. 2012;31:134–9.

    PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Kang KB, Karas FI, Rai R, Hallak JA, Kang JJ, de la Cruz J, et al. Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study. PLoS One. 2018;13:e0192381.

    PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Casaroli-Marano RP, Nieto-Nicolau N, Martinez-Conesa EM, Edel M. A BA-P. Potential role of induced pluripotent stem cells for cell-based therapy of the ocular surface. J Clin Med. 2015;4:318–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Kumagai Y, Kurokawa MS, Ueno H, Kayama M, Tsubota K, Nakatsuji N, et al. Induction of corneal epithelium-like cells from cynomolgus monkey embryonic stem cells and their experimental transplantation to damaged cornea. Cornea. 2010;29:432–8.

    PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Hayashi R, Ishikawa Y, Ito M, Kageyama T, Takashiba K, Fujioka T, et al. Generation of corneal epithelial cells from induced pluripotent stem cells derived from human dermal fibroblast and corneal limbal epithelium. PLoS One. 2012;7:e45435.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Sareen D, Saghizadeh M, Ornelas L, Winkler MA, Narwani K, Sahabian A, et al. Differentiation of human limbal-derived induced pluripotent stem cells into limbal-like epithelium. Stem Cells Trans Med. 2014;3:1002–12.

    CAS  Article  Google Scholar 

  42. 42.

    Mikhailova A, Ilmarinen T, Ratnayake A, Petrovski G, Uusitalo H, Skottman H, et al. Human pluripotent stem cell-derived limbal epithelial stem cells on bioengineered matrices for corneal reconstruction. Exp Eye Res. 2016;146:26–34.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Erbani J, Aberdam D, Larghero J, Vanneaux V. Pluripotent stem cells and other innovative strategies for the treatment of ocular surface diseases. Stem Cell Rev Rep. 2016;12:171–8.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Hayashi R, Ishikawa Y, Sasamoto Y, Katori R, Nomura N, Ichikawa T, et al. Co-ordinated ocular development from human iPS cells and recovery of corneal function. Nature. 2016;531:376–80.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Gomes JA, Geraldes Monteiro B, Melo GB, Smith RL, Cavenaghi Pereira da Silva M, Lizier NF, et al. Corneal reconstruction with tissue-engineered cell sheets composed of human immature dental pulp stem cells. Invest Ophthalmol Vis Sci. 2010;51:1408–14.

    PubMed  Article  Google Scholar 

  46. 46.

    Meyer-Blazejewska EA, Call MK, Yamanaka O, Liu H, Schlotzer-Schrehardt U, Kruse FE, et al. From hair to cornea: toward the therapeutic use of hair follicle-derived stem cells in the treatment of limbal stem cell deficiency. Stem Cells. 2011;29:57–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Reza HM, Ng BY, Gimeno FL, Phan TT, Ang LP. Umbilical cord lining stem cells as a novel and promising source for ocular surface regeneration. S Stem Cell Rev Rep. 2011;7:935–47.

    PubMed  Article  Google Scholar 

  48. 48.

    Ma Y, Xu Y, Xiao Z, Yang W, Zhang C, Song E, et al. Reconstruction of chemically burned rat corneal surface by bone marrow-derived human mesenchymal stem cells. Stem Cells. 2006;24:315–21.

    PubMed  Article  Google Scholar 

  49. 49.

    Vereb Z, Poliska S, Albert R, Olstad OK, Boratko A, Csortos C, et al. Role of human corneal stroma-derived mesenchymal-like stem cells in corneal immunity and wound healing. Sci Rep. 2016;6:26227.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Zeppieri M, Salvetat ML, Beltrami A, Cesselli D, Russo R, Alcalde I, et al. Adipose derived stem cells for corneal wound healing after laser induced corneal lesions in mice. J Clin Med. 2017;6(12).

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  51. 51.

    Galindo S, Herreras JM, Lopez-Paniagua M, Rey E, de la Mata A, Plata-Cordero M, et al. Therapeutic effect of human adipose tissue-derived mesenchymal stem cells in experimental corneal failure due to limbal stem cell niche damage. Stem Cells. 2017;35:2160–74.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Venugopal B, Shenoy SJ, Mohan S, Anil Kumar PR, Kumary TV. Bioengineered corneal epithelial cell sheet from mesenchymal stem cells-a functional alternative to limbal stem cells for ocular surface reconstruction. J Biomed Mater Res Part B Appl Biomater. 2019.

  53. 53.

    Shibata S, Hayashi R, Okubo T, Kudo Y, Baba K, Honma Y, et al. The secretome of adipose-derived mesenchymal stem cells attenuates epithelial-mesenchymal transition in human corneal epithelium. Regen Ther. 2019;11:114–22.

    PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7(344):re8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  55. 55.

    Wright B, Mi S, Connon CJ. Towards the use of hydrogels in the treatment of limbal stem cell deficiency. Drug Discov Today. 2013;18:79–86.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Han B, Schwab IR, Madsen TK, Isseroff RR. A fibrin-based bioengineered ocular surface with human corneal epithelial stem cells. Cornea. 2002;21:505–10.

    PubMed  Article  Google Scholar 

  57. 57.

    Yanez-Soto B, Leonard BC, Raghunathan VK, Abbott NL, Murphy CJ. Effect of stratification on surface properties of corneal epithelial cells. Invest Ophthalmol Vis Sci. 2015;56:8340–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Jie J, Yang J, He H, Zheng J, Wang W, Zhang L, et al. Tissue remodeling after ocular surface reconstruction with denuded amniotic membrane. Sci Rep. 2018;8:6400.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  59. 59.

    Lu H, Wang F, Mei H, Wang S, Cheng L. Human adipose mesenchymal stem cells show more efficient angiogenesis promotion on endothelial colony-forming cells than umbilical cord and endometrium. Stem Cells Int. 2018;2018:7537589.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  60. 60.

    Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J. 2012;76:1750–60.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  61. 61.

    Carlson MA, Calcaterra J, Johanning JM, Pipinos II, Cordes CM, Velander WH. A totally recombinant human fibrin sealant. J Surg Res. 2014;187:334–42.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  62. 62.

    Wang O, Ismail A, Fabian FM, Lin H, Li Q, Elowsky C, et al. A totally recombinant fibrin matrix for mesenchymal stem cell culture and delivery. J Biomed Mater Res Pt A. 2018;106:3135–42.

    CAS  Article  Google Scholar 

Download references


We thank the Experimental Microscopy Platform, Singapore Eye Research Institute (SERI) for light and fluorescence microscopies, Translational Preclinical Model Platform, SERI, and SingHealth Experimental Medicine Center (SEMC), The Academia, Singapore, for assisting the animal experiments and ocular examinations.


Singapore National Research Foundation under its Translational and Clinical Research (TCR) program (NMRC/TCR/008-SERI/2013) and Clinician Scientist Award-Senior Investigator Category (JRNMRR163801), National Medical Research Council, Ministry of Health, Singapore.

Author information




GHY and JSM contributed to conceptualization and supervision. FB, TWG, and MS contributed to the data curation, investigation, and methodology. JSM contributed to the funding acquisition. GHY, FB, and JSM contributed to the writing—review and editing. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Gary Hin-Fai Yam or Jodhbir S. Mehta.

Ethics declarations

Ethics approval and consent to participate

Animal experiments were conducted according to the regulation of the ARVO statement for the Use of Animals in Ophthalmic and Vision Research. The experimental protocol was approved by the Institutional Animal Care and Use Committee of SingHealth, Singapore (2012/SHS/768).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1:

Figure S1. Human ADSC characterization. Figure S2. Human ADSC characterization using trilineage cell differentiation. Table S1. Primary antibody information.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bandeira, F., Goh, T., Setiawan, M. et al. Cellular therapy of corneal epithelial defect by adipose mesenchymal stem cell-derived epithelial progenitors. Stem Cell Res Ther 11, 14 (2020).

Download citation


  • Corneal epithelium
  • Limbal stem cell deficiency
  • Adipose mesenchymal stem cells
  • Mesenchymal-epithelial transition
  • Epithelial reconstruction